Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0IGWYN
ADC Name
WO2016205176A1 ADC-101
Synonyms
Thio Hu Anti-Ly6E 9B12.v12 LC K149C-(LD-1)
   Click to Show/Hide
Organization
Genentech, Inc.
Drug Status
Investigative
Indication
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
Drug-to-Antibody Ratio
2
Antibody Name
Thio hu Anti-Ly6E 9B12.v12 LC K149C
  Antibody Info 
Antigen Name
Lymphocyte antigen 6E (LY6E)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
WO2016205176A1_ADC-101 linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 90.91
%
HCC1569 cells
Breast ductal carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 95.17
%
HCC1569 cells
Breast ductal carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 97.02
%
HCC1569 cells
Breast ductal carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 90.91% (Day 14) Moderate LY6E expression (LY6E++)
Method Description
Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million HCC1569 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.2 mg/kg) through tail vein.

   Click to Show/Hide
In Vivo Model HCC1569 CDX model
In Vitro Model Breast ductal carcinoma HCC1569 cells CVCL_1255
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 95.17% (Day 14) Moderate LY6E expression (LY6E++)
Method Description
Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million HCC1569 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.5 mg/kg) through tail vein.

   Click to Show/Hide
In Vivo Model HCC1569 CDX model
In Vitro Model Breast ductal carcinoma HCC1569 cells CVCL_1255
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 97.02% (Day 14) Moderate LY6E expression (LY6E++)
Method Description
Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million HCC1569 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (1 mg/kg) through tail vein.

   Click to Show/Hide
In Vivo Model HCC1569 CDX model
In Vitro Model Breast ductal carcinoma HCC1569 cells CVCL_1255
References
Ref 1 Antibodies and immunoconjugates; 2016-12-22.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.